Effectiveness of adjunctive antidepressant treatment for bipolar depression

New England Journal of Medicine

Volumn 356, Issue 17, 2007, Pages 1711-1722

  Sachs, Gary S ^a   Nierenberg, Andrew A ^a   Calabrese, Joseph R ^c   Marangell, Lauren B ^d   Wisniewski, Stephen R ^e   Gyulai, Laszlo ^g   Friedman, Edward S ^f   Bowden, Charles L ^h   Fossey, Mark D ⁱ   Ostacher, Michael J ^a   Ketter, Terence A ^j   Patel, Jayendra ^k   Hauser, Peter ^l   Rapport, Daniel ^m   Martinez, James M ^d   Allen, Michael H ⁿ   Miklowitz, David J ^o   Otto, Michael W ^b   Dennehy, Ellen B ^p   Thase, Michael E ^f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b BOSTON UNIVERSITY   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁱ UNIVERSITY OF OKLAHOMA   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^l OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^m MEDICAL COLLEGE OF OHIO   (United States)

ⁿ UNIVERSITY OF COLORADO   (United States)

^o UNIVERSITY OF COLORADO   (United States)

^p PURDUE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; MOOD STABILIZER; PAROXETINE; PLACEBO;

ABDOMINAL PAIN; ABNORMAL VISION; ADJUVANT THERAPY; ADOLESCENT; AFFECT; AGITATION; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIPOLAR DEPRESSION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MANIA; NAUSEA; PATIENT MONITORING; PRIORITY JOURNAL; RASH; REMISSION; RISK ASSESSMENT; SCHOOL CHILD; SEXUAL DYSFUNCTION; SIDE EFFECT; SWELLING; TREATMENT OUTCOME; TREMOR;

EID: 34247476744     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa064135     Document Type: Article

References (26)

1. Murray CJ, Lopez AD, Jamison DT. The global burden of disease in 1990: summary results, sensitivity analysis and future directions. Bull World Health Organ 1994;72:495-509.
2. Kessler RC, Demler O, Frank RG, et al. Prevalence and treatment of mental disorders, 1990 to 2003. N Engl J Med 2005;352:2515-23.
3. Simon GE, Unutzer J. Health care utilization and costs among patients treated for bipolar disorder in an insured population. Psychiatr Serv 1999;50:1303-8.
4. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-7.
5. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003;64:680-90, 738-9.
6. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163:217-24.
7. Goodwin GM. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2003;17:147, 149-73.
8. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas Implementation of Medication Algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005;66:870-86.
9. Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006;163:232-9.
10. Ghaemi SN, Hsu DJ, Thase ME, et al. Pharmacological treatment patterns at study entry for the first 500 STEP-BD participants. Psychiatr Serv 2006;57:660-5.
11. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-12.
12. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapinefluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60:1079-88. [Erratum, Arch Gen Psychiatry 2004;61:176.]
13. Sachs GS, Thase ME, Otto MW, et al. Rationale, design, and methods of the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Biol Psychiatry 2003;53:1028-42.
14. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I. History, rationale, and description. Arch Gen Psychiatry 1992;49:624-9.
15. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59:Suppl 20:22-57.
16. Goldberg JF, Allen MH, Miklowitz DA, et al. Suicidal ideation and pharmacotherapy among STEP-BD patients. Psychiatr Serv 2005;56:1534-40.
17. Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry 1994;55:391-3.
18. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry (in press).
19. Sachs GS, Guille C, McMurrich SL. A Clinical Monitoring Form for mood disorders. Bipolar Disord 2002;4:323-7.
20. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27. [Erratum, Arch Gen Psychiatry 2005:62:709.]
21. Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-47.
22. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002;159:Suppl:1-50.
23. Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry 2002;63:508-12.
24. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006;189:124-31. [Erratum, Br J Psychiatry 2006;189:569.]
25. Frank E, Swartz HA, Mallinger AG, Thase ME, Weaver EV, Kupfer DJ. Adjunctive psychotherapy for bipolar disorder: effects of changing treatment modality. J Abnorm Psychol 1999;108:579-87.
26. Scott J, Paykel E, Morriss R, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomised controlled trial. Br J Psychiatry 2006;188:313-20.